Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 13,612 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Pregnancy Related, Atopic Dermatitis
Interventions: Ruxolitinib Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 15 Years to 50 Years · Female only
Enrollment: 958 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 1
States / cities: Morrisville, North Carolina

Conditions: Lymphedema, Breast Cancer
Interventions: arm circumference measurement, Bioimpedance spectroscopy; Procedure · Device
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, HER2/Neu-positive Breast Cancer
Interventions: Capecitabine, Lapatinib; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Hamilton, New Jersey • New Brunswick, New Jersey

Conditions: Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Interventions: Not listed
Lead sponsor: Adela, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Duarte, California • Miami, Florida • Gainesville, Georgia + 14 more

Conditions: Atopic Dermatitis
Interventions: Roflumilast Cream 0.05%, Roflumilast Cream 0.15%, Vehicle Cream; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 17
States / cities: Scottsdale, Arizona • San Diego, California • Hialeah, Florida + 14 more

Conditions: Melanoma
Interventions: epothilone b; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 6
States / cities: Aurora, Colorado • Tampa, Florida • The Bronx, New York + 3 more

Conditions: Breast Cancer, Stage III Breast Cancer, Breast Cancer Female, Stage I Breast Cancer, Stage II Breast Cancer
Interventions: THRIVE, Health Education Support Program; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 65 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Boston, Massachusetts • Cleveland, Ohio • Pittsburgh, Pennsylvania + 1 more

Conditions: Psoriasis, Psoriasis Vulgaris, Skin Diseases
Interventions: Activapatch intellidose 2.5 using active Iontophoresis, Activapatch intellidose 2.5 using inactive Iontophoresis, Dexamethasone; Device · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Breast Cancer
Interventions: letrozole 2.5 mg; Drug
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Ocular Rosacea, Dry Eye
Interventions: Intense Pulsed Light Treatment (IPL), Meibomian Gland Expression; Device · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Diabetic Foot Ulcers, Diabetic Foot Wounds
Interventions: Collagenase Santyl Ointment, Placebo Comparator; Biological · Other
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Cervical Cancer, Lung Cancer, Prostate Cancer, Vaginal Cancer, Ovarian Cancer, Breast Cancer, Bladder Cancer
Interventions: Questioners, STAR website; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,007 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Breast Cancer Female, Muscle Weakness
Interventions: Creatine; Dietary Supplement
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: educational intervention, counseling intervention, telephone-based intervention, questionnaire administration, quality-of-life assessment; Other · Behavioral · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Phototoxicity
Interventions: MC2-01 Cream, irradiation, MC2-01 Cream, no irradiation, MC2-01 vehicle, irradiation, MC2-01 vehicle, no irradiation, Control, irradiation; Drug
Lead sponsor: MC2 Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions: VDPHL01, Placebo; Drug
Lead sponsor: Veradermics, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Encino, California + 37 more

Conditions: Advanced Cutaneous Melanoma
Interventions: ITIL-168; Biological
Lead sponsor: Instil Bio; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 20
States / cities: La Jolla, California • Los Angeles, California • Stanford, California + 14 more

Conditions: Melanoma
Interventions: Minimally invasive inguinal lymph node dissection; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 11
States / cities: Scottsdale, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more

Conditions: Onychomycosis/Onycholysis and Tinea Pedis
Interventions: Placebo, Terbinafine Hydrochloride, Terbinafine; Drug
Lead sponsor: NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.); Industry
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Advanced Malignancies, Metastatic Cancer
Interventions: INCAGN01876, Epacadostat, Pembrolizumab; Drug
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Los Angeles, California • Hackensack, New Jersey

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Months to 80 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 7
States / cities: La Jolla, California • Denver, Colorado • Chicago, Illinois + 3 more

Conditions: Psoriasis
Interventions: Text reminder; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Mastitis
Interventions: Osteopathic Manipulative Treatment (OMT); Procedure
Lead sponsor: Western University of Health Sciences; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pomona, California

Conditions: Breast Cancer, Breast Neoplasms
Interventions: fenretinide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer

Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis

EPO906 Therapy in Patients With Advanced Melanoma

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients

Iontophoresis in Psoriasis

An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg

Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea

Wound Edge Changes Following Treatment With Santyl

Internet-based System for Cancer Patients to Self-report Toxicity

THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation

Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy

Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream

Safety and Efficacy of VDPHL01 in Males With AGA

ITIL-168 in Advanced Melanoma

Minimally Invasive Groin Dissection for Melanoma

Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Identifying Genetic Determinants of Eczema Herpeticum and Other Viral Infections in Individuals With Atopic Dermatitis

Deucravacitinib Adherence Study

Osteopathic Manipulative Treatment for Recurrent Mastitis

A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer